Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.

Metabolism: clinical and experimental - 1 Apr 2026

Gerlach Peter A, Gadgaard Sarina, Madsen Jakob S, Lindquist Peter, Lorente Javier Sanchez, Faas Felix, Gabe Maria B N, Rosenkilde Mette M, Hauser Alexander S

Abstract excerpt

OBJECTIVE: The glucagon-like peptide-2 receptor (GLP-2R) is recognized as a potential target for the treatment of obesity and type 2 diabetes (T2D). Yet, the impact and mechanism of GLP-2R activation on these metabolic traits remain unclear in humans. METHODS: We conducted in vitro pharmacological characterization of 30 naturally occurring GLP-2R missense variants identified from the UK Biobank, assessing...

Topics

Join the communities discussing this publication.

Biological Specimen Banks
Cyclic AMP
Diabetes Mellitus, Type 2
Genetic Predisposition to Disease
Obesity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Signal Transduction

Source

Identifiers

PMID: 41519224
DOI: 10.1016/j.metabol.2025.156489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.PMID 41519224Read ↗

Human GLP1R variants affecting GLP1R cell surface expression contribute to impaired glucose control and increased adipositySemantic proximity Read ↗

Rare Heterozygous Loss-of-Function Variants in the Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes.Semantic proximity Read ↗

Molecular and in vivo phenotyping of missense variants of the human glucagon receptorSemantic proximity Read ↗

Determinants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank studySemantic proximity Read ↗

Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeuticsSemantic proximity Read ↗

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity Read ↗

Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus.Semantic proximity Read ↗

Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes.Semantic proximity Read ↗

Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against ObesitySemantic proximity Read ↗

Functional and genetic epidemiological characterisation of the FFAR4 (GPR120) p.R270H variant in the Danish population.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.